Slides
Page 1
Viyash INVESTOR PRESENTATION Q1 FY27 VIYASH SCIENTIFIC LIMITED August 12 , 2026 1
Page 2
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results Our performance in Q1 FY27 reflects the continued success of our integration efforts and the strength of the combined entity. This quarter's results are underpinned by robust execution, improving operating leverage, and a well-defined growth strategy. The acquisition of Bio For Life in Italy is a significant step in advancing our strategic focus on the companion animal segment, providing us with market access and a platform to launch our product portfolio in key European markets. As we move forward, our focus remains on disciplined execution, operational efficiency, and strategic investments in line with our long-term strategy for sustainable growth. Dr Hari Babu Bodepudi Viyash Scientific Limited Marching ahead as an Integrated platform
Page 3
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results 3 Q1FY27 Financial Snapshot
Page 4
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results 4 Viyash Scientific : Q1 FY27 Performance Highlights All values in ₹ Mn Revenues ₹9,464 Million +19.5% YoY EBITDA¹ ₹2,047 Million +59.2 % YoY EBITDA Margin 21.6% +530 bps YoY Net Debt to LTM EBITDA¹ 0.1x 0.2x in Q4 FY26 Net Debt - ₹ 1,661 Notes: 1. EBITDA are adjusted for ESOP costs Net Debt- ₹ 861 Mn
Page 5
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results 5 Sustained Sales Growth with Consistent EBITDA Expansion 7,292 7,313 7,740 7,723 7,916 8,503 8,584 9,200 9,464 6,000 7,000 8,000 9,000 10,000 Q1'25 Q2 '25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Q1'27 Sales 3,580 3,741 3,971 4,075 4,111 4,718 4,675 5,071 5,121 49.1% 51.2% 51.3% 52.8% 51.9% 55.5% 54.5% 55.1% 54.1% 35.0% 45.0% 55.0% 65.0% 2,000 3,000 4,000 5,000 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Q1'27 Gross Margin GM GM% 1,020 1,033 1,127 1,221 1,286 1,883 1,854 2,001 2,047 14.0% 14.1% 14.6% 15.8% 16.2% 22.1% 21.6% 21.7% 21.6% 0.0% - 500 1,000 1,500 2,000 Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Q1'27 EBITDA¹ EBITDA EBITDA% 1.4x 1.4x 1.2x 1.0x 1.0x 0.7x 0.4x 0.2x 0.1x 0.0x 0.5x 1.0x 1.5x Q1'25 Q2'25 Q3'25 Q4'25 Q1'26 Q2'26 Q3'26 Q4'26 Q1'27 Net Debt to EBITDA¹ *EBITDA adjusted for ESOP All values in ₹ Mn
Page 6
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results 6 o ESOP cost increase on account of incremental ESOP grants pursuant to the scheme of amalgamation o Finance Cost reduction on account of the reduction in debt. Particulars Q1 Q1 Grw YoY % Q4 Grw QoQ % FY26 FY25 Grw YoY %FY27 FY26 FY26 Revenue from Operations 9,464 7,916 19.5% 9,200 2.9% 34,203 30,068 13.8% Material Consumption (4,343) (3,805) (4,128) (15,627) (14,702) Gross Margin 5,121 4,111 24.6% 5,071 1.0% 18,576 15,367 20.9% % Gross margin 54.1% 51.9% 55.1% 54.3% 51.1% Employee Benefit Expenses (1,381) (1,258) 9.7% (1,445) -4.5% (5,293) (4,959) 6.7% Operating Expenses (1,696) (1,573) 7.8% (1,689) 0.5% (6,378) (5,984) 6.6% Exchange Gain / (Loss) 3 6 63 120 (23) EBITDA¹ 2,047 1,286 59.2% 2,001 2.3% 7,025 4,400 59.6% % EBITDA 21.6% 16.2% 21.7% 20.5% 14.6% ESOP cost (246) (130) (53) (362) (561) Exceptional Items - (13) (0) (442) (816) IndAS 29 Adjustment (14) 37 (42) (17) 29 Other Income 80 62 96 315 329 Finance Cost (125) (204) (145) (692) (864) Depreciation (618) (556) (604) (2,336) (2,387) Earnings Before Tax 1,124 483 132.8% 1,252 -10.2% 3,490 132 2569.4% % Earning Before Tax 11.9% 6.1% 13.6% 10.2% 0.4% Taxes (331) (115) (589) (1,244) 26 Earnings After Tax 793 369 114.9% 664 19.4% 2,246 158 1334.0% Notes: 1. EBITDA are adjusted for ESOP costs Viyash Consolidated Financials All values in ₹ Mn
Page 7
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results Business Updates
Page 8
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results 8*Adjustment on account of hyperinflation in Turkey as per Ind AS 29 # Provision for customer claim on shipments in prior years Revenue Distribution Q1 Q4 12M FY27 FY26 YoY % FY26 QoQ % FY26 FY25 YoY % Formulations 5,547 4,170 33% 4,991 11% 18,657 15,828 18% Europe 1,847 1,640 13% 1,733 7% 6,682 5,614 19% Emerging Markets 2,008 1,480 36% 1,725 16% 6,305 5,142 23% India 430 263 63% 379 13% 1,405 1,155 22% USA 1,262 787 60% 1,154 9% 4,266 3,916 9% APIs 3,833 3,692 4% 3,836 0% 14,906 13,747 8% Other Sales 75 92 184 423 372 Global Sales 9,455 7,954 19% 9,011 5% 33,987 29,946 13% One Offs # (56) (56) (74) Adjustment* - Ind AS 29* 8 19 189 273 196 Reported Sales 9,464 7,916 20% 9,200 3% 34,203 30,068 14% Business Segments Performance All values in ₹ Mn
Page 9
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results Bio For Life acquisition in Italy 9 Acquisition of Bio for Life in Italy aligned with our Companion strategy Companion animal portfolio (85-90 products) that can be extended to other core markets 02 Launch our global pipeline in Italy; salesforce has 85% vet clinic coverage in Italy 03 Provides access to a large companion animal market in Italy 01 Strong talent addition in Italy 04 Execution of SPA: 21st July 2026 Expected Closing Timeline: September 2026
Page 10
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results 10 4 Regulatory Audits 66 Customer audits Facility Inspections Regulatory Approvals Launches Products Filed Validations Completed R&D Pipeline 3 APIs- (USDMF-1 ; EDMF- 1; CEP-1) 2 FDF - US (2) 6 APIs ( 2-MENA, 1-EU, 1 CHINA, 1 LATAM) 4 FDF 8 APIs – USDMF (1),USVMF(1), Russia (2), Taiwan (1), Singapore (1), Malaysia (1), US VMF (1) 2 FDF - US (2) 15 APIs 4 FDF API: 85+ Human FDF: 24+ Animal FDF: 81+ Additional Business Updates
Page 11
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results Viyash at a Glance
Page 12
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results Who we are? 12 We are an integrated pharmaceutical platform across animal and human health backed by science and IP Diversified Product Portfolio API - 90+ Human Health - 30+ Animal Health- 140+ Global Presence 150+ Countries 250+ global customers Backward Integration 16 Manufacturing facilities Backward Integration for key APIs IP & Technology Driven 250+ Scientists 175+ Patents Filed 1,000+ Registrations Strong Management Team Industry leaders with 30+ years experience
Page 13
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results Viyash Scientific: Key Milestones 13 Integration & Global Reach Unified manufacturing operations, expanded R&D to over 200 scientists, filed 175+ patents* , and strengthened global partnerships and regulatory capabilities. Specialization & Growth Focused on new geographies and specialized animal healthcare segments, building a strong global manufacturing and distribution network. 2020–2025 Global Expansion Established Alivira as a dedicated animal health brand. Expanded operations across Europe, Latin America, and emerging markets with USFDA veterinary API approvals. 2014–2019 Foundation & Evolution Originated as Visistha Trades, transitioned into a focused pharmaceutical and animal health company, and rebranded as SeQuent Scientific Limited. 1985–2013 Scale & Expansion Acquisition of Mylan's API and formulation units in Vizag and Mumbai. Strategic investment by the Carlyle Group. Acquisition of Symed Labs and Appco Pharma LLC, strengthening global capabilities Foundation & Early Growth Founded in February 2019 by Dr Haribabu Bodepudi. Rapid expansion through acquisitions of Vindhya Pharma and Vandana Life Sciences, and establishment of API R&D infrastructure. Viyash Life Sciences SeQuent Scientific Scientific Limited 2025 onwards
Page 14
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results 16 world class manufacturing facilities 10 API MANUFACTURING SITES API Formulations USA Spain Turkey Brazil II Brazil I India – AH Formulations
Page 15
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results Our R&D landscape R&D centre Location Capabilities / dosage forms Technologies & infrastructure R&D members API R&D India (Hyderabad, Telangana) • Scalable complex APIs incl. high-potent (OEB 4/5) & cytotoxic; iron-complex, inorganic & complex molecules • 20+ chemical R&D labs; dedicated process- safety lab; high-end analytical equipment for process dev & validation 225+ Formulation R&D – Human Health (Viyash / Appco) India • OSD (Non-Onco) & Onco-Cytotoxic; generics plus complex pharmaceuticals • Formulation development, analytical method development, tech transfer, QA, regulatory affairs 60+ Formulation R&D – Animal Health (Alivira) India, Spain, Turkey • Generic & complex dosage forms — solid, liquid & sterile (oral solutions/suspensions, powders, premixes) • Formulation development, analytical method development, tech transfer, QA, regulatory filings 55+ Spain Brazil Turkey India • Animal Formulations • Human Formulations • API
Page 16
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results Board of Directors Dr. Kamal Sharma Chairman and Independent Director Mr. Milind Sarwate Independent Director Ms. Revati Kasture Independent Director Mr. Anuj Poddar Non-executive Director Mr. Amit Jain Non-executive Director Mr. Abhiroop Jayanthi Non-executive Director Dr. Haribabu Bodepudi Managing Director and Group CEO Mr. Rajaram Narayanan Executive Director and CEO- Animal Health Mr. Srinivas Vasireddy Executive Director
Page 17
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results 17 Human formulations API & CDMO Animal formulations Companion Animals Farm Animals Long Term Strategy ✓ API integrated play ✓ Complex products including oncology ✓ New product development ✓ Market expansion ✓ Manufacturing expansion ✓ M&A ✓ Portfolio completion ✓ Geography extension ✓ Portfolio expansion ✓ Day 1 launch ✓ Complex CDMO Growth drivers
Page 18
Certain statements in this document that are not historical facts are forward looking statements. Such forward -looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause a ctual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances. Registered Office: Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India Websites: www.viyash.com | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: VIYASH ISIN: INE807F01027 For details, feel free to contact: Yoshita Vora Company Secretary +91 22 4111 4777 investorrelations@viyash.com Abhishek Singhal Investor Relations Consultant abhishek@arunya.co.in 18
Page 19
R-127 G-127 B-127 R-189 G-230 B-247 R-145 G-213 B-242 R-61 G-175 B-46 R-156 G-226 B-146 R-145 G-229 B-0 R-0 G-161 B-224 R-0 G-101 B-179 R-163 G-143 B-187 R-85 G-67 B-113 R-118 G-92 B-150 R-219 G-217 B-217 R-43 G-131 B-35 Text Colors White R-255 G-255 B-255 Dark Blue R-0 G-74 B-136 Blue R-0 G-161 B-224 Use colors in preferred order for best results Plot No.290, Srivalli's Corporate, Road No.6, Kakatiya Hills, Madhapur Hyderabad Rangareddy TG 500081, India Thank You Copyright © 2021. Viyash. All Rights Reserved. info@viyash.com | www.viyash.com